Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wheat bran is the fiber-rich outer layer of the wheat kernel (*Triticum aestivum*), primarily composed of insoluble non-starch polysaccharides such as arabinoxylan and cellulose. It is widely utilized as a dietary intervention for gastrointestinal and metabolic health. Its primary mechanism involves increasing fecal bulk and reducing intestinal transit time, which alleviates constipation. Additionally, wheat bran serves as a prebiotic substrate for colonic microbiota, leading to the production of short-chain fatty acids (SCFAs) like butyrate and acetate. These SCFAs are associated with the stimulation of glucagon-like peptide-1 (GLP-1) secretion, which may improve insulin sensitivity and promote satiety. Clinical research has explored its role in weight management, the prevention of colorectal adenoma recurrence, and the management of irritable bowel syndrome (IBS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wheat bran.